Alpha Cognition’s candidate oral tablet ALPHA-1062, for mild to moderate Alzheimer’s disease, showed efficacy as a bioequivalent substitute for the approved therapy Razadyne (galantamine), according to top-line data from a trial with healthy volunteers. Per this new data, as a delayed-release tablet, ALPHA-1062 showed…
Every September, during World Alzheimer’s Month, supporters around the world call attention to Alzheimer’s disease and other types of dementia in an effort to challenge stereotypes about the conditions. World Alzheimer’s Day is Sept. 21. More than 50 million people globally are thought to be living with dementia,…
The optimal dose of under-the-skin (subcutaneous) lecanemab, Eisai’s experimental therapy for early Alzheimer’s disease, has been determined in a modeling study. The dose is currently being evaluated in the Phase 3 Clarity AD open-label extension study (NCT03887455). “Eisai’s broad clinical program for lecanemab continues to deliver data…
Trametinib, an oral medication approved to treat certain cancers, improved cognition and neuronal health in a mouse model of Alzheimer’s disease, according to a new study. Data suggest the treatment helped to clear toxic protein aggregates from nerve cells. The study, “MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation…
Intranasal, or into-the-nose, delivery of foralumab, an investigational antibody-based treatment being developed by Tiziana Life Sciences, restored the activity of microglial cells and improved cognition in a mouse model of Alzheimer’s disease. Formerly known as NI-0401, foralumab acts to lower inflammation by blocking the activity of CD3, a protein…
The U.S. Food and Drug Administration (FDA) has kept to its initial decision to reject a request by Acadia Pharmaceuticals to expand Nuplazid (pimavanserin) to treat hallucinations and delusions associated with Alzheimer’s disease-related psychosis. In a complete response letter (CRL) indicating it had finished its review of the…
Buntanetap, an experimental treatment for neurodegenerative diseases, was safe, lowered toxic protein accumulation, reduced inflammation, and improved cognition in people with Alzheimer’s disease. This was according to data from a Phase 2a trial (NCT04524351) that evaluated the investigational therapy against a placebo…
COR588, Quince Therapeutics’ investigational oral small molecule for mild to moderate Alzheimer’s disease, appears to be safe and well tolerated, according to results from a Phase 1 trial, the company announced. (The company was known as Cortexyme until Aug. 1.) The recently completed single and multiple ascending dose clinical…
Treatment with Alzheon‘s oral candidate ALZ-801 (valiltramiprosate) lowered levels of a key biomarker for Alzheimer’s disease — and led to significant memory improvements in people with the neurodegenerative disorder. That’s according to data from a six-month interim analysis of an ongoing Phase 2 biomarker…
Chronic treatment with HT-ALZ, Hoth Therapeutics‘ investigational oral therapy for Alzheimer’s disease, led to significant cognitive improvements in a mouse model of the neurodegenerative condition. The data were collected as part of Hoth’s ongoing sponsored research agreement with investigators at Washington University in St. Louis, Missouri, led by…
Get regular updates to your inbox.